Clinical Trial Search

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 6.83; 7.15; 6.84 millimoles per Liter…

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change

Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin

Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants

Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl

Primary: Program Enrollment Rate (%) — 14 Percentage of participants

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Percentage of Participants Who Had One or More Adverse Reactions — 5.41; 1.20; 0.98; 0.00 Percentage of Participants

Primary: Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint — -0.60; -0.80; -1.24; -1.41 percentage of glycosylated hemoglobin — p=0.0109

Primary: Mean Blood Glucose Concentration After First Day of Treatment — 9.5; 9.4 mmol/L

Primary: Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint — 18.5 percentage of participants

Primary: Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A — 2; 2; 1; 1 participants

Primary: Number of Index Dates — 91634; 33238; 28211; 26192 Number of Prescriptions

Primary: Number of Participants With Abnormal Physical Examination Findings

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% — 22.4; 8.8 percentage of participants — p=0.0499

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Number of Participants With Clinically Significant Adverse Effects — 9; 8; 9; 8 Participants

Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values

Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants

Primary: Change of HbA1c From Baseline at Week 12 — 2.14; 2.10; 1.95; 2.02 ln(percent) — p=<0.0001

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001

Primary: Change in HgbA1c — -1.9 percentage of glycosylated hemoglobin

Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 5; 0; 3 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to…